EMAGIX is an early stage biomedical company that has developed an algorithm-driven approach for diagnosis of retinal and brain vascular injury.
There is an emerging consensus of the key role of leaky blood vessels in the development of a wide range of ophthalmic and neurologic disorders. With the growth in the number of people affected by diabetes, Emagix is focused on preventing the devastating consequence of visual loss.
The company’s technology is a game changer that will identify subtle changes in vascular functions and monitor the rate of progression and response to treatment. The end result will improve patient care and save money.